



OpGen to Present Advancements in Antibiotic Susceptibility and Whole Genome Sequencing at ASM Microbe 2017

May 25, 2017

GAITHERSBURG, Md., May 25, 2017 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today announced that data on its Acuitas[®] Rapid Test in development and Acuitas Whole Genome Sequence Analysis will be presented at ASM Microbe 2017 being held June 1-5, 2017 in New Orleans, LA. These data will demonstrate the company's ability to predict phenotypic resistance across antibiotic classes for Gram-negative infections using rapid genetic testing and predictive algorithms from its Acuitas Lighthouse[®] Knowledgebase. It will also showcase advances in being able to discriminate bacterial strains using more genes to solve current limitations with conventional strain typing methods.

The details for the poster presentations at ASM Microbe are as follows:

Session info: 186 - AAID01 - Antibacterial Resistance: Genomics and New Methodologies to Trace Antimicrobial Resistance

Poster title: Predicting Antibiotic Resistance in Gram-Negative Bacilli by Rapid Detection of Resistance Genes (#87)

Presenter: Terry Walker, Ph.D.

Date and time: Saturday, June 3, 12:15 – 2:15 PM CEDT

Location: Exhibit Hall D, Exhibit and Poster Hall

Session info: 186 - AAID01 - Antibacterial Resistance: Genomics and New Methodologies to Trace Antimicrobial Resistance

Poster title: Core Genome Multilocus Sequence Typing Scheme for High-Resolution Typing of *Escherichia coli* (#72)

Presenter: Weizhong Chang, Ph.D.

Date and time: Saturday, June 3, 12:15 – 2:15 PM CEDT

Location: Exhibit Hall D, Exhibit and Poster Hall

About OpGen

OpGen, Inc. is harnessing the power of informatics and genomic analysis to provide complete solutions for patient, hospital and network-wide infection prevention and treatment. Learn more at www.opgen.com and follow OpGen on Twitter and LinkedIn.

OpGen[®], Acuitas[®], Acuitas Lighthouse[®] and QuickFISH[®] are registered trademarks of OpGen, Inc.

OpGen Contact:

Michael Farmer

Director, Marketing

240-813-1284

mfarmer@opgen.com

InvestorRelations@opgen.com

Investor and Media Contact:

Cammy Duong

MacDougall Biomedical Communications

781-591-3443

cduong@macbiocom.com



OpGen, Inc.